Thiruvanantha Puram Today

Rheumatoid Arthritis Clinical Trial Insight, Pipeline Assessment, Companies, Emerging Drugs by DelveInsight

 Breaking News
  • No posts were found

Rheumatoid Arthritis Clinical Trial Insight, Pipeline Assessment, Companies, Emerging Drugs by DelveInsight

September 03
13:47 2020
Rheumatoid Arthritis Clinical Trial Insight, Pipeline Assessment, Companies, Emerging Drugs by DelveInsight

“Rheumatoid Arthritis (RA) Pipeline Insight, 2020”

(Albany,US) DelveInsight has launched a new report on “Rheumatoid Arthritis (RA) Pipeline Insight, 2020“.

 

Rheumatoid Arthritis (RA) Pipeline Insight, 2020” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Rheumatoid Arthritis (RA) market. A detailed picture of the Rheumatoid Arthritis (RA) pipeline landscape is provided, which includes the disease overview and Rheumatoid Arthritis (RA) treatment guidelines.

The assessment part of the report embraces in-depth Rheumatoid Arthritis (RA) commercial assessment and clinical assessment of the Rheumatoid Arthritis (RA) pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Rheumatoid Arthritis (RA) collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

 

The key players in Rheumatoid Arthritis market are:

  • Galapagos NV/Gilead Sciences
  • R-Pharm
  • Abivax
  • And many others

 

Request for Free Sample Report: https://www.delveinsight.com/sample-request/rheumatoid-arthritis-ra-pipeline-insight

 

Drugs covered:

  • Filgotinib
  • Olokizumab
  • ABX464
  • And many others

 

Rheumatoid Arthritis treatment landscape has progressed from the last two decade, including the diagnosis and treatment. Albeit, presently there is no cure for the disease, the goals of therapy are to decrease pain, inflammation control, preserve the ability of the patient to function in activities of daily living and work and avert joint destruction. Pharmacists and other healthcare professionals play a vital role in caring for Rheumatoid Arthritis patients. The pharmacologic approaches have relied on combinations of non-steroidal anti-inflammatory drugs (NSAIDs), analgesics, glucocorticoids (prednisone, methylprednisone), disease-modifying anti-rheumatic drugs (DMARDs) and biologics.

Corticosteroids, including prednisone, prednisolone and methylprednisolone, are potent and quick-acting anti-inflammatory medications. They may be used to get potentially damaging inflammation under control and may be needed to control severe polyarticular disease until disease-modifying antirheumatic drugs (DMARDs) have been added and become useful.
There is now a better comprehension of the mechanisms/pathways involved in the disease, permitting site-specific drug development. There are two major types of Disease-Modifying Antirheumatic Drugs (DMARDs): biological and synthetic.

Conventional, synthetic DMARDs (csDMARDs) are not site-specific, and they do not have precise mechanisms of action for relieving the disease. Synthetic DMARDs targets to a particular site. Biological DMARDs are also site-specific (e.g., targeting TNF, IL-6, IL-1, B cells, or T cells).

 

Request for Free Sample Report: https://www.delveinsight.com/sample-request/rheumatoid-arthritis-ra-pipeline-insight

 

Key Questions

  • What are the current options for Rheumatoid Arthritis (RA) treatment?
  • How many companies are developing therapies for the treatment of Rheumatoid Arthritis (RA)
  • What are the principal therapies developed by these companies in the industry?
  • How many therapies are developed by each company for the treatment of Rheumatoid Arthritis (RA)?
  • How many Rheumatoid Arthritis (RA) emerging therapies are in early-stage, mid-stage, and late stage of development for the treatment of Rheumatoid Arthritis (RA)?
  • Out of total pipeline products, how many therapies are given as a monotherapy and in combination with other therapies? 
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, and major licensing activities that will impact Rheumatoid Arthritis (RA) market? 
  • Which are the dormant and discontinued products and the reasons for the same?
  • What is the unmet need for current therapies for the treatment of Rheumatoid Arthritis (RA)?  
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing Rheumatoid Arthritis (RA) therapies? 
  • What are the clinical studies going on for Rheumatoid Arthritis (RA) and their status?
  • What are the results of the clinical studies and their safety and efficacy? 
  • What are the key designations that have been granted for the emerging therapies for Rheumatoid Arthritis (RA)
  • How many patents are granted and pending for the emerging therapies for the treatment of Rheumatoid Arthritis (RA)

 

Request for Free Sample Report: https://www.delveinsight.com/sample-request/rheumatoid-arthritis-ra-pipeline-insight

 

Table of Contents:

1. Report Introduction

2. Rheumatoid Arthritis (RA) 

3. Rheumatoid Arthritis (RA) Current Treatment Patterns

4. Rheumatoid Arthritis (RA) – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Rheumatoid Arthritis (RA) Late Stage Products (Phase-III)

7. Rheumatoid Arthritis (RA) Mid Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Rheumatoid Arthritis (RA) Discontinued Products

13. Rheumatoid Arthritis (RA) Product Profiles

14. Rheumatoid Arthritis (RA) Key Companies

15. Rheumatoid Arthritis (RA) Key Products

16. Dormant and Discontinued Products

17. Rheumatoid Arthritis (RA) Unmet Needs

18. Rheumatoid Arthritis (RA) Future Perspectives

19. Rheumatoid Arthritis (RA) Analyst Review  

20. Appendix

21. Report Methodology

 

Request for Detailed TOC: https://www.delveinsight.com/sample-request/rheumatoid-arthritis-ra-pipeline-insight

 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/rheumatoid-arthritis-ra-pipeline-insight

Related Articles